News

Adlai Nortye Reduces IPO Size

1 Mins read

Adlai Nortye, a biotechnology company, is adjusting its initial public offering (IPO) to decrease its investment in program development. According to a Securities and Exchange Commission filing on Wednesday, the company is reducing the number of American depositary shares offered from 3 million to 2.5 million.

Previously, Adlai Nortye had indicated a price range of $22 to $26 per share. However, the estimated price per share for the IPO will now be $23. As a result of these changes, the company expects net proceeds of $54.2 million instead of the initially projected $67.9 million.

Out of the revised amount, Adlai Nortye plans to allocate $29.7 million towards its pipeline of programs and $13.5 million towards general working and corporate purposes. This differs from their previous plan in August, which aimed to invest $41.5 million in program development and $15.5 million for corporate purposes.

Despite the adjustments to their IPO, Adlai Nortye remains committed to investing $46.7 million in funding the registrational trial for the AN2025 inhibitor, as well as milestone payments for its development and commercial launch if approved.

Related posts
News

Funeral home owner accused of stashing decaying bodies expected to plead guilty in federal court

1 Mins read
DENVER – A funeral home owner in Colorado accused of storing nearly 190 decomposing bodies in a room-temperature building and defrauding the…
News

Has the Airbnb bubble burst?

2 Mins read
Only 4% of Americans are considering Airbnb for their next vacation according to a survey from forex giant Travelex. As part of…
News

Tinubu has changed narrative of NDDC, says Ogbuku, MD

21 Mins read
Managing director of the Niger Delta Development Commission (NDDC), Dr. Samuel Ogbuku, in this interview, spoke on the leadership reforms in the…

Leave a Reply

Your email address will not be published. Required fields are marked *